ESTROFEM

Main information

  • Trade name:
  • ESTROFEM 28 TAB
  • Dosage:
  • 2MG
  • Pharmaceutical form:
  • TAB
  • Composition:
  • 28
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • ESTROFEM 28 TAB
    India
  • Language:
  • English

Other information

Status

  • Source:
  • Central Drugs Standard Control Organization
  • Last update:
  • 09-08-2016

18-10-2018

Unauthorized "Surfaz-SN Triple Action Cream" seized from Mississauga store may pose serious health risks

Unauthorized "Surfaz-SN Triple Action Cream" seized from Mississauga store may pose serious health risks

Health Canada seized “Surfaz-SN Triple Action Cream”—an unauthorized skin cream promoted for antifungal, antibacterial and anti-inflammatory use—because it is labelled to contain prescription drugs (betamethasone dipropionate and neomycin sulphate). The product was seized from Kaf African Caribbean Market (2642 Liruma Road, Unit 2A) in Mississauga, Ontario.

Health Canada

18-10-2018

Scientific Opinion on Flavouring Group Evaluation 201 Revision 2 (FGE.201Rev2): 2‐alkylated, aliphatic, acyclic alpha,beta‐unsaturated aldehydes and precursors, with or without additional double‐bonds, from chemical subgroup 1.1.2 of FGE.19

Scientific Opinion on Flavouring Group Evaluation 201 Revision 2 (FGE.201Rev2): 2‐alkylated, aliphatic, acyclic alpha,beta‐unsaturated aldehydes and precursors, with or without additional double‐bonds, from chemical subgroup 1.1.2 of FGE.19

Published on: Wed, 17 Oct 2018 00:00:00 +0200 The Panel on Food Additives and Flavourings of the European Food Safety Authority was requested to consider in this revision 2 of Flavouring Group Evaluation 201, the additional data on genotoxicity submitted by the Industry on two substances, 2‐methylpent‐2‐enal [FL‐no: 05.090] and 2 methylcrotonaldehyde [FL‐no: 05.095], from subgroup 1.1.2 of FGE.19. In FGE.201Rev1, the Panel concluded that further data were required in order to clarify the genotoxic poten...

Europe - EFSA - European Food Safety Authority Publications

18-10-2018

Training courses in systematic reviews or in specific steps of systematic review for EFSA Risk Assessment

Training courses in systematic reviews or in specific steps of systematic review for EFSA Risk Assessment

Published on: Wed, 17 Oct 2018 00:00:00 +0200 The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. Th...

Europe - EFSA - European Food Safety Authority Publications

17-10-2018

Enforcement Report for the Week of October 17, 2018

Enforcement Report for the Week of October 17, 2018

Recently Updated Records for the Week of October 17, 2018 Last Modified Date: Monday, October 15, 2018

FDA - U.S. Food and Drug Administration

20-9-2018

Report of the third Joint Meeting of the ECDC's Food‐ and Waterborne Diseases and Zoonoses Network and of the EFSA's Zoonoses Monitoring Data Network

Report of the third Joint Meeting of the ECDC's Food‐ and Waterborne Diseases and Zoonoses Network and of the EFSA's Zoonoses Monitoring Data Network

Published on: Wed, 19 Sep 2018 00:00:00 +0200 The third Joint Meeting of the ECDC's Food‐ and Waterborne Disease and Zoonoses Network and of the EFSA's Zoonoses Monitoring Data Network was held on 16 and 17 October 2017 in Parma. The meeting was constructed around the principle of ‘One health approach to collaborative response to foodborne disease outbreaks in EU/EEA’ and served as an opportunity for public health authorities and food safety/veterinary authorities to meet and exchange information on the...

Europe - EFSA - European Food Safety Authority Publications

18-9-2018

Peer review of the pesticide risk assessment of the active substance beta‐cyfluthrin

Peer review of the pesticide risk assessment of the active substance beta‐cyfluthrin

Published on: Fri, 14 Sep 2018 00:00:00 +0200 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authorities of the rapporteur Member State Germany and co‐rapporteur Member State Hungary for the pesticide active substance beta‐cyfluthrin are reported. The context of the peer review was that required by Commission Implementing Regulation (EU) No 844/2012. The conclusions were reached on the basis of the evaluation of the representative uses of b...

Europe - EFSA - European Food Safety Authority Publications

7-9-2018

Orphan designation:  Recombinant human beta-glucuronidase (vestronidase alfa),  for the: Treatment of mucopolysaccharidosis type VII (Sly syndrome)

Orphan designation: Recombinant human beta-glucuronidase (vestronidase alfa), for the: Treatment of mucopolysaccharidosis type VII (Sly syndrome)

On 21 March 2012, orphan designation (EU/3/12/973) was granted by the European Commission to NDA Regulatory Science Ltd, United Kingdom, for recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type VII (Sly syndrome).

Europe - EMA - European Medicines Agency

23-8-2018

Companies cease sales of e-liquids with labeling or advertising that resembled kid-friendly foods following FDA, FTC warnings

Companies cease sales of e-liquids with labeling or advertising that resembled kid-friendly foods following FDA, FTC warnings

FDA announced that all 17 manufacturers, distributors, and retailers that were warned in May have stopped selling the e-liquids used in e-cigarettes with labeling or advertising resembling kid-friendly food products.

FDA - U.S. Food and Drug Administration

20-8-2018

August 17, 2018: Unlicensed Pharmacy Technician Pleads Guilty to Working at New England Compounding Center

August 17, 2018: Unlicensed Pharmacy Technician Pleads Guilty to Working at New England Compounding Center

August 17, 2018: Unlicensed Pharmacy Technician Pleads Guilty to Working at New England Compounding Center

FDA - U.S. Food and Drug Administration

1-8-2018

Unauthorized skin creams and lotions sold at various retailers in Quebec may pose serious health risks

Unauthorized skin creams and lotions sold at various retailers in Quebec may pose serious health risks

Health Canada seized eight unauthorized skin lotions and creams from Ayotai Canada because they are labelled to contain a prescription drug (clobetasol propionate or betamethasone dipropionate). The unauthorized lotions and creams were distributed by Ayotai and sold by various retailers in Quebec.

Health Canada

18-7-2018

Orphan designation:  Recombinant humanised anti-human interleukin-1 beta monoclonal antibody,  for the: Treatment of Behçet’s disease

Orphan designation: Recombinant humanised anti-human interleukin-1 beta monoclonal antibody, for the: Treatment of Behçet’s disease

On 1 October 2010, orphan designation (EU/3/10/796) was granted by the European Commission to XOMA Ireland Ltd, Ireland, for recombinant humanised anti-human interleukin-1 beta monoclonal antibody for the treatment of Behçet’s disease.

Europe - EMA - European Medicines Agency

18-7-2018

Hy-Vee Voluntarily Recalls Spring Pasta Salad Due to Reported Illnesses

Hy-Vee Voluntarily Recalls Spring Pasta Salad Due to Reported Illnesses

WEST DES MOINES, Iowa (July 17, 2018) — Hy-Vee, Inc., based in West Des Moines, Iowa, is voluntarily recalling its Hy-Vee Spring Pasta Salad due to the potential that it may be contaminated with Salmonella. The potential for contamination was brought to Hy-Vee’s attention last night when approximately 20 illnesses in Minnesota, South Dakota, Nebraska and Iowa were potentially linked back to customers consuming the salad. The voluntary recall includes Hy-Vee Spring Pasta Salads in both 1 pound (16 oz.) an...

FDA - U.S. Food and Drug Administration

17-7-2018

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

FDA - U.S. Food and Drug Administration

24-9-2018

EndolucinBeta (ITG Isotope Technologies Garching GmbH)

EndolucinBeta (ITG Isotope Technologies Garching GmbH)

EndolucinBeta (Active substance: Lutetium (177 Lu) chloride) - PSUSA - Modification - Commission Decision (2018)6236 of Mon, 24 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3999/PSUSA/10391/201712

Europe -DG Health and Food Safety

21-9-2018

Scientific guideline:  Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health, draft: consultation open

Scientific guideline: Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health, draft: consultation open

The objective of this document is to review available information on the use of aminopenicillins and their beta-lactamase inhibitor combinations in veterinary medicines in the EU, their effect on the emergence of antimicrobial resistance (AMR) and the potential impact of resistance on human and animal health. The document provides information for the risk profiling, as recommended by the Antimicrobial Advice ad hoc Expert Group (AMEG) of the EMA.

Europe - EMA - European Medicines Agency

17-9-2018

Agenda:  Agenda - CHMP agenda of the 17-20 September 2018 meeting

Agenda: Agenda - CHMP agenda of the 17-20 September 2018 meeting

Europe - EMA - European Medicines Agency

28-8-2018

LIFMIOR (Pfizer Europe MA EEIG)

LIFMIOR (Pfizer Europe MA EEIG)

LIFMIOR (Active substance: etanercept) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5700 of Tue, 28 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4167T/17

Europe -DG Health and Food Safety

17-8-2018

EU/3/17/1870 (Pharma Gateway AB)

EU/3/17/1870 (Pharma Gateway AB)

EU/3/17/1870 (Active substance: Thymidine and deoxycytidine) - Transfer of orphan designation - Commission Decision (2018)5403 of Fri, 17 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/317/16/T/01

Europe -DG Health and Food Safety

15-8-2018

EU/3/18/1994 (Quality Regulatory Clinical Ireland Limited)

EU/3/18/1994 (Quality Regulatory Clinical Ireland Limited)

EU/3/18/1994 (Active substance: Ivosidenib) - Transfer of orphan designation - Commission Decision (2018)5555 of Wed, 15 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/172/17/T/01

Europe -DG Health and Food Safety

7-8-2018

EU/3/18/1996 (Worphmed Srl)

EU/3/18/1996 (Worphmed Srl)

EU/3/18/1996 (Active substance: Melatonin) - Transfer of orphan designation - Commission Decision (2018)5409 of Tue, 07 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/227/17/T/01

Europe -DG Health and Food Safety

6-8-2018

Avonex (Biogen Netherlands B.V.)

Avonex (Biogen Netherlands B.V.)

Avonex (Active substance: Interferon Beta - 1a) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5392 of Mon, 06 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/102/T/178

Europe -DG Health and Food Safety

2-8-2018

EU/3/16/1660 (Orchard Therapeutics Ltd)

EU/3/16/1660 (Orchard Therapeutics Ltd)

EU/3/16/1660 (Active substance: Autologous CD34+ cells transduced with lentiviral vector encoding the human beta globin gene) - Transfer of orphan designation - Commission Decision (2018)5288 of Thu, 02 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/024/16/T/02

Europe -DG Health and Food Safety

27-7-2018

EU/3/14/1263 (bluebird bio (Germany) GmbH)

EU/3/14/1263 (bluebird bio (Germany) GmbH)

EU/3/14/1263 (Active substance: Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human beta A-T87Q-globin gene) - Transfer of orphan designation - Commission Decision (2018)5035 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/184/13/T/01

Europe -DG Health and Food Safety

27-7-2018

EU/3/12/1091 (bluebird bio (Germany) GmbH)

EU/3/12/1091 (bluebird bio (Germany) GmbH)

EU/3/12/1091 (Active substance: Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human betaA-T87Q-globin gene) - Transfer of orphan designation - Commission Decision (2018)5032 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/146/12/T/01

Europe -DG Health and Food Safety

27-7-2018

EU/3/18/2013 (Roche Registration GmbH)

EU/3/18/2013 (Roche Registration GmbH)

EU/3/18/2013 (Active substance: Polatuzumab vedotin) - Transfer of orphan designation - Commission Decision (2018)5054 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/231/17/T/01

Europe -DG Health and Food Safety

27-7-2018

EU/3/17/1932 (Millendo Therapeutics SAS)

EU/3/17/1932 (Millendo Therapeutics SAS)

EU/3/17/1932 (Active substance: Synthetic cyclic 8 amino acid analogue of human unacylated ghrelin) - Transfer of orphan designation - Commission Decision (2018)5049 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/066/17/T/01

Europe -DG Health and Food Safety

26-7-2018

Regulatory and procedural guideline:  EudraVigilance release notes v.1.17

Regulatory and procedural guideline: EudraVigilance release notes v.1.17

This document lists and briefly describes the following areas for the releases of EVWEB starting with the release on 22 November 2017.

Europe - EMA - European Medicines Agency

23-7-2018

Plegridy (Biogen Netherlands B.V.)

Plegridy (Biogen Netherlands B.V.)

Plegridy (Active substance: peginterferon beta-1a) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4881 of Mon, 23 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2827/T/49

Europe -DG Health and Food Safety

23-7-2018

Qarziba (EUSA Pharma (UK) Limited)

Qarziba (EUSA Pharma (UK) Limited)

Qarziba (Active substance: dinutuximab beta) - Centralised - Yearly update - Commission Decision (2018)4886 of Mon, 23 Jul 2018

Europe -DG Health and Food Safety

18-7-2018

Agenda:  Agenda - CVMP agenda of the 17-19 July 2018 meeting

Agenda: Agenda - CVMP agenda of the 17-19 July 2018 meeting

Committee for Medicinal Products for Veterinary Use - Draft agenda of July 2018 meeting

Europe - EMA - European Medicines Agency

17-7-2018

Agenda:  Agenda - COMP agenda of the 17-19 July 2018 meeting

Agenda: Agenda - COMP agenda of the 17-19 July 2018 meeting

Draft agenda for the meeting on 17-19 July 2018

Europe - EMA - European Medicines Agency

17-7-2018

Rebif (Merck Serono Europe Limited)

Rebif (Merck Serono Europe Limited)

Rebif (Active substance: Interferon beta-1a) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4780 of Tue, 17 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/136/T/135

Europe -DG Health and Food Safety

17-7-2018

Naglazyme (BioMarin International Limited)

Naglazyme (BioMarin International Limited)

Naglazyme (Active substance: galsulfase) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4782 of Tue, 17 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/640/T/72

Europe -DG Health and Food Safety

17-7-2018

Firdapse (BioMarin Europe Ltd)

Firdapse (BioMarin Europe Ltd)

Firdapse (Active substance: amifampridine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4779 of Tue, 17 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1032/T/57

Europe -DG Health and Food Safety

17-7-2018

Karvea (Sanofi-Aventis groupe)

Karvea (Sanofi-Aventis groupe)

Karvea (Active substance: Irbesartan) - Centralised - Yearly update - Commission Decision (2018)4781 of Tue, 17 Jul 2018

Europe -DG Health and Food Safety

17-7-2018

Agenda:  Agenda - Follow up information session on the TransCelerate initiative, 17 July 2018

Agenda: Agenda - Follow up information session on the TransCelerate initiative, 17 July 2018

Follow up information session on the TransCelerate initiative

Europe - EMA - European Medicines Agency

11-7-2018

Betaferon (Bayer AG)

Betaferon (Bayer AG)

Betaferon (Active substance: Interferon beta-1b) - Centralised - Yearly update - Commission Decision (2018)4527 of Wed, 11 Jul 2018

Europe -DG Health and Food Safety

10-7-2018

Fertavid (Merck Sharp and Dohme B.V.)

Fertavid (Merck Sharp and Dohme B.V.)

Fertavid (Active substance: follitropin beta) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4474 of Tue, 10 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1042/T/39

Europe -DG Health and Food Safety

10-7-2018

Puregon (Merck Sharp and Dohme B.V.)

Puregon (Merck Sharp and Dohme B.V.)

Puregon (Active substance: follitropin beta) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4479 of Tue, 10 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/86/T/97

Europe -DG Health and Food Safety

9-7-2018

 Minutes of the PRAC meeting 14-17 May 2018

Minutes of the PRAC meeting 14-17 May 2018

Europe - EMA - European Medicines Agency

29-6-2018

EU/3/07/505 (Faron Pharmaceuticals Limited)

EU/3/07/505 (Faron Pharmaceuticals Limited)

EU/3/07/505 (Active substance: Interferon beta) - Amendment of orphan designation - Commission Decision (2018)4186 of Fri, 29 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/080/17

Europe -DG Health and Food Safety